Executive Summary
Biofrontera AG et al. challenged U.S. Patent No. 11,697,028 held by DUSA Pharmaceuticals, Inc., alleging obviousness under 35 U.S.C. § 103. The challenge focuses on the combination of prior art references to demonstrate that specific Photodynamic Therapy (PDT) illuminator claims are unpatentable.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Biofrontera AG et al. vs Sun Pharmaceutical Industries, Inc. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
3D Systems Corporation et al.vsIntrepid Automation, Inc.
The USPTO granted institution for IPR2025-01241 and several other proceedings, allowing the merits phase of review to proceed.
Samsung Electronics Co., Ltd. et al.vsOura Health Oy et al.
Samsung Electronics has filed a Petition challenging all 22 claims of Oura Health's '147 Patent, alleging obviousness under 35 U.S.C. § 103. The challenge relies on multiple combinations of prior art references, including Yuen, Schröder, and Mestas.
Menard, Inc.vsSignify Holdings B.V. et al.
The PTAB denied a request to vacate a Final Written Decision (FWD) because the Petitioner introduced new arguments regarding obviousness in its reply brief. The Board found that the initial petition lacked sufficient particularity to support the claims' unpatentability.
Tesla, Inc.vsGraphite Charging Company LLC
The PTAB issued a Final Written Decision finding that the claims were not unpatentable by either anticipation (Cooley) or obviousness (Wang/AESO Report). The Board adopted the Patent Owner's claim construction of 'current' as referring to the present, rejecting the petitioner's interpretation.
Cytek Biosciences, Inc.vsBeckman Coulter, Inc. et al.
The PTAB denied institution of a Post-Grant Review (PGR2025-00084) because the petitioner failed to demonstrate that any challenged patent claims were unpatentable.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.